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To establish the significance of glucocerebrosidase gene (GBA) carrier status on motor im-
pairment in a large cohort of patients with incident Parkinson disease (PD).
Methods
Three European population-based studies followed 528 patients with PD from diagnosis. A
total of 440 with genomic DNA from baseline were assessed for GBA variants. We evaluated
motor and functional impairment annually using the Unified Parkinson’s Disease Rating Scale
(UPDRS) motor and activities of daily living (ADL) sections. Differential effects of classes of
GBA variants on disease progression were evaluated using mixed random and fixed effects
models.
Results
A total of 387 patients with idiopathic disease (age at baseline 70.3 ± 9.5 years; 60.2%male) and
53 GBA carriers (age at baseline 66.8 ± 10.1 years; 64.2% male) were included. The motor
profile of the groups was clinically indistinguishable at diagnosis. GBA carriers showed faster
annual increase in UPDRS scores measuring ADL (1.5 point per year, 95% confidence interval
[CI] 1.1–2.0) and motor symptoms (2.2 points per year, 95% CI 1.3–3.1) compared to
noncarriers (ADL, 1.0 point per year, 95%CI 0.9–1.1, p = 0.003; motor, 1.3 point per year, 95%
CI 1.1–1.6, p = 0.007). Simulations of clinical trial designs showed that recruiting only GBA
carriers can reduce trial size by up to 65% compared to a trial recruiting all patients with PD.
Conclusion
GBA variants are linked to a more aggressive motor disease course over 7 years from diagnosis
in patients with PD. A better understanding of PD progression in genetic subpopulations may
improve disease management and has direct implications for improving the design of clinical
trials.
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Parkinson disease (PD) is a neurodegenerative disorder de-
fined by the presence of motor symptoms and signs, though
nonmotor symptoms are common in all stages of the disease.
The disease course is typically progressive and in the advanced
stages, motor impairment results in significant disability.
The glucocerebrosidase gene (GBA) encodes the lysosomal
enzyme β-glucocerebrosidase. Mutations and polymorphisms
inGBA are estimated to be found in up to 12% of patients with
PD of European descent, and mutations in 15%–20% of
Ashkenazi Jewish cases, making GBA the most significant
genetic risk factor for PD.1–5 GBA-associated PD has been
shown to manifest at a younger age and with a lower median
survival time from diagnosis compared to idiopathic PD.6–8
Further,GBAmutation status is an independent risk factor for
cognitive impairment.3,5,9–11
PD is primarily a movement disorder yet few studies have
analyzed the effect of GBA carrier status on motor decline in
early PD. In this study, we address this using longitudinal data
from 3 deeply phenotyped population-based studies of in-
cident PD in Northern Europe to comprehensively survey the
progression of motor impairment in early PD. By determining
the role of GBA variants in the evolution of motor and
functional decline, we provide important new insights into the
distinct clinical profile of GBA-associated PD, with impor-
tance for both more individualized patient care and more
efficient clinical trial design.
Methods
Cohorts, Approvals, and Patient Consents
The participants in this study take part in the Norwegian
ParkWest study, the Swedish NYPUM study, and the Scottish
PINE study, 3 prospective population-based longitudinal in-
cidence studies of PD (recruitment running between 2002
and 2009) with similar study design.12–15 A total of 212 pa-
tients were enrolled in the ParkWest study, 211 in the PINE
study, and 182 in the NYPUM study. The consent rate to
participation among incident patents was 80% in the
ParkWest study, 94% in the PINE study, and 94% in the
NYPUM study. The patients are under continued follow-up,
and only those with a confirmed clinical or pathologic (if
performed postmortem) diagnosis of PD according to the UK
Brain Bank criteria at their latest or final clinical visit were
included. Since enrollment, 70 had a diagnosis other than PD
during follow-up. Furthermore, 57 declined genotyping, 31
have no available DNA sample or DNA was not extractable,
and 7 did not consent to follow-up. The remaining 440
patients were eligible for this study and the 7-year clinical
visits were complete.
Standard Protocol Approvals, Registrations,
and Patient Consents
The Western Norway Regional Committee for Medical and
Health Research Ethics, the Regional Ethics Review Board in
Umeå, and the Multi-Centre Research Ethics Committee for
Scotland approved the respective studies. Written informed
consent was obtained from all patients participating in the
study (consent for research).
Clinical Assessment
The clinical assessments have been described in detail and the
same procedures were followed in each cohort.12–15 Briefly, a
study neurologist performed general medical and neurologic
examinations and semi-structured interviews at baseline to
obtain medical, drug, and family history (defined as the report
of a first- or second-degree relative with PD). We reassessed
the patients at regular follow-up visits and offered home visits
to those unable or not willing to meet at the clinic to minimize
attrition bias. We used the Hoehn & Yahr (H&Y) scale to rate
disease stage16 and the Unified Parkinson’s Disease Rating
Scale (UPDRS)17 sections II (activities of daily living [ADL])
and III (motor examination). In addition to overall motor
impairment, we assessed the severity of specific motor fea-
tures of PD by the summation of the relevant UPDRS III
items as follows: tremor (items 20–21), rigidity (items 22),
bradykinesia (items 23–26, 31), and axial impairment (items
27–30). Assessment of nonmotor features included the Mini-
Mental State Examination (MMSE). Antiparkinsonian treat-
ment was prescribed and adjusted throughout the study by a
study neurologist according to best clinical judgment. We
calculated levodopa-equivalent doses (LED) in accordance
with published recommendations.18
Genetic Analysis
The presence of GBA mutations (rs76763715/N370S,
rs421016/L444P, and rs781152868/Y135C) or GBA poly-
morphisms (rs2230288/E326K, rs75548401/T369M, and
rs369068553/V460L) in the study population has been de-
scribed in detail.5 Briefly, genomic DNA was extracted from
peripheral blood samples collected at baseline using standard
methods. A total of 188 patients of the ParkWest cohort were
characterized by whole exome sequencing and 5 non-
synonymous variants were detected (N370S, T369M, E326K,
V460L, and Y135C) and confirmed by sequencing.5 These
variants were genotyped in all available samples using Taq-
Man single nucleotide polymorphism genotyping assay
(Thermo Fisher Scientific). The L444P genotype was
Glossary
ADL = activities of daily living; CI = confidence interval; GBA = glucocerebrosidase gene; H&Y = Hoehn & Yahr; LED =
levodopa-equivalent dose;MMSE =Mini-Mental State Examination; PD = Parkinson disease; PPMI = Parkinson’s Progression
Markers Initiative; UPDRS = Unified Parkinson’s Disease Rating Scale.
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determined using PCR–restriction fragment length poly-
morphism assays (primer sequences and reaction conditions
available on request) and all mutations confirmed by direct
sequencing of the PCR- product.19,20
All amino acid substitutions are numbered excluding the 39-
residue signal peptide.
Statistical Methods
“GBA carriers” included all patients carrying any of the
detected nonsynonymousGBA variants. We further splitGBA
carriers into “polymorphism carriers” (E326K, T369M, or
V460L) and “deleterious carriers” (Y135C, N370S, or L444P)
as described.5 We compared between-group differences at
baseline using t tests, Mann-Whitney U tests, and χ2 tests as
appropriate.
We applied mixed linear regression analysis to determine the
association between GBA genotype and longitudinal motor
measures assessed using repeat UPDRS ADL and motor
scores. Mixed models use all available data during follow-up,
can handle missing at random data, and can properly account
for correlation between repeated measurements: at each visit
between 94.8% and 99.8% of patients had complete UPDRS
ADL or motor score data. We performed the analyses without
adjustment and with adjustment for sex, study cohort, age,
and duration of motor symptoms at baseline. The effect sizes
were comparable after additional adjustment for LED at each
visit (data not shown). The time of the repeated measures was
computed in years from the baseline date. All models have
fixed effect of time, as well as random intercepts, random
effect of time, and first-order autoregressive residual co-
variance structure. Tremor and axial impairment scores were
log-transformed before analysis. Plot of predictive margins
was created in Stata using margins and marginsplot. As esti-
mates of associations may be affected by dropouts due to
death,21 we performed post hoc sensitivity analysis by joint
modeling of longitudinal measures of motor function and
time to death using function stjm in Stata.22 Whereas the
longitudinal measures of UPDRS ADL ormotor score and the
event times were found to be related, the estimated associa-
tions and effect sizes between GBA carrier status and the
longitudinal measures were very similar to the presented re-
sults (data not shown).
Statistical analyses were conducted using IBM SPSS Statistics
(Armonk, NY) version 26.0 or Stata and 2-tailed p values
<0.05 considered significant.
Power Calculations for the Clinical Trial
We performed power calculations for a hypothetical clinical
trial of a putative neuroprotective agent with 36 months
follow-up. The first scenario assumed that all newly diagnosed
patients with PD (“all-comers”) would be eligible for the trial,
and the second limited trial selection to carriers of a GBA
variant. The expected trajectories for the placebo group were
set to those estimated in the present study from population-
averaged models adjusted for age, sex, cohort, and disease
duration (for all patients or only GBA carriers, as appropri-
ate). The covariance matrices were based on separate esti-
mates of both variance and correlation, that is, respectively
137 and 0.77 for all comers and 102 and 0.67 forGBA carriers.
The treated individuals were assumed to experience a 50%
reduction in their motor decline (i.e., the intervention halves
disease progression). The required sample sizes to obtain a
power of between 60% and 96% to detect such differences in
slopes (i.e., the between–within subjects interaction effect) at
a 5% significance level were estimated using Stata function
power repeated, which incorporates F tests with Greenhouse-
Geisser correction for lack of sphericity.
Data Availability
Anonymized data are available on request by any qualified
investigator for purposes of replicating procedures and results.
Results
Baseline Profile of PD‐GBA Carriers
A total of 440 patients with PD were included in the study.
Their mean age at baseline was 69.9 (±9.6) years, with
60.7% (267) male (table 1). The median duration of follow-
up was 7.0 years (interquartile range 2.0). During the study,
117 patients died (26.6%) and 25 (5.7%) withdrew from the
study (figure 1).GBA variants were identified in 53 patients:
29 E326K, 16 T369M, 6 L444P, 1 Y135C, 1 N370S, and
1 V460L variant.5 Carriers of any GBA variant observed
the first motor signs of PD at an earlier age than noncarriers
(p = 0.022) and were also younger at the age of PD diagnosis
(p = 0.014), as previously reported.5 However, GBA carriers
and noncarriers did not differ at the time of diagnosis in
terms of overall motor severity or ADL function, nor se-
verity of tremor, rigidity, bradykinesia, or axial impairment
(all p > 0.1).
Effect of GBA on Motor and Functional Decline
Linear mixed models with adjustment for age, sex, study co-
hort, and duration of motor symptoms at baseline demon-
strated a 69% more rapid motor decline per year in GBA
carriers than noncarriers, with an annual increase in UPDRS
motor score of 2.2 (95% CI 1.3–3.1 points) vs 1.3 point (95%
CI 1.1–1.6 point), respectively. This difference was significant
(0.9 point difference per year; 95% CI 0.2–1.5; p = 0.007)
(table 2 and figure 2). We observed a similar effect on the rate
of functional decline, with carriers of a GBA variant predicted
to exhibit an annual increase in UPDRS ADL score of 1.5
point (95% CI 1.1 to 2.0), compared to only 1.0 point (95%
CI 0.9–1.1 point) in noncarriers (0.5 point difference per
year; 95% CI 0.2–0.9; p = 0.003). The effect sizes were
comparable for adjusted and unadjusted models (data not
shown).
Both the polymorphism and the deleterious mutation carrier
groups showed faster motor and functional decline compared
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to noncarriers (table 2). The predicted difference in change in
annual UPDRS ADL score compared to noncarriers was
highest for the deleterious mutation carrier group (0.9 point
difference per year; 95% CI 0.1–1.7; p = 0.029) and more
modest for the polymorphism carrier group (0.4 point dif-
ference per year; 95% CI 0.1–0.8; p = 0.016). The same
tendency was observed for change in UPDRSmotor score per
year, with a more pronounced motor decline predicted for
carriers of aGBAmutation (1.2 point difference per year; 95%
CI −0.3 to 2.7; p = 0.11) than a polymorphism (0.8 point
difference per year; 95% CI 0.1–1.5; p = 0.022).
Examination of the change in specific motor symptoms
revealed that the difference in motor decline was mainly
driven by changes in the scores for bradykinesia and rigidity.
Bradykinesia score was predicted to increase by 0.5 point per
year more in carriers of a GBA variant compared to noncar-
riers (95% CI 0.2–0.8; p = 0.002). Further, the annual change
in the bradykinesia subscore was significantly larger in carriers
of a GBA mutation than in carriers of a GBA polymorphism
when compared to noncarriers (table 3). Rigidity score also
increased faster when comparing GBA carriers to noncarriers
(0.2 point difference per year; 95%CI 0.0–0.3; p = 0.038), but
no significant differences were observed for rigidity when
comparing either GBA mutation or polymorphism carriers to
noncarriers (table 3).
Hypothetical Power Analysis for a Stratified
Clinical Trial Targeting GBA-PD
Enriching a clinical trial for subgroups of patients predicted to
progress faster in the primary outcome can considerably re-
duce trial size. To assess the reductions in trial size that could
be achieved by recruiting only carriers of GBA variants com-
pared to an all-comer design, we ran clinical trial power
analysis for a hypothetical drug predicted to halve the pro-
gression of motor impairment (measured using UPDRS
motor score). In a 3-year trial designed to have 80% power to
detect between–within subjects interaction effect, we found
that the required size of the trial was reduced from 1,446
participants if all newly diagnosed patients were eligible to 506
in the GBA-carrier design, providing a 65% reduction in the
number of individuals that need to be enrolled (figure 3).
Table 1 Demographic and Clinical Measures at the Time




Total 440 387 53
Male, n (%) 267 (60.7) 233 (60.2) 34 (64.2)
Age at baseline,
y, mean (±SD)
69.9 (9.6) 70.3 (9.5) 66.8 (10.1)
Age at motor onset,
y, mean (±SD)
67.8 (9.7) 68.1 (9.6) 65.0 (9.8)
Family history 103 (23.4) 92 (23.8) 11 (20.8)
Years of education 11.4 (3.4) 11.4 (3.4) 11.6 (5.0)
MMSE, median (IQR) 29.0 (3.0) 29.0 (3.0) 28.3 (2.5)
H&Y, median (IQR) 2.0 (1.0) 2.0 (1.0) 2.0 (1.0)
UPDRS ADL (IQR) 9.0 (6.0) 9.0 (6.0) 8.0 (7.0)
UPDRS motor (IQR) 23.0 (16.0) 23.0 (17.0) 21.0 (15.5)
UPDRS motor subscores,
median (IQR)
Tremor 3.0 (4.0) 3.0 (4.0) 3.0 (4.0)
Bradykinesia 11.0 (8.0) 11.0 (8.25) 10.0 (7.5)
Rigidity 4.0 (5.0) 4.0 (4.0) 4.0 (5.0)
Axial impairment 2.0 (2.0) 2.0 (3.0) 2.0 (2.0)
Abbreviations: ADL = activities of daily living; H&Y = Hoehn & Yahr score;
IQR = interquartile range; MMSE = Mini-Mental State Examination; UPDRS =
Unified Parkinson’s Disease Rating Scale.
Figure 1 Flowchart of Study Participants
Overviewof patient inclusion frombaseline until the 7-year visit. The number
of patients in the study at each visit is shown. Withdrawals and deaths be-
tween visits are shown in dashed boxes. The number of patients carrying a
GBA polymorphism/mutation is shown in bold. The flowchart is simplified for
readability.
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Discussion
In this study, we comprehensively explored the relationship
between GBA carrier status and long-term motor and func-
tional decline in newly diagnosed patients with PD followed
from time of diagnosis. Taking advantage of longitudinal data
from 3 population-based studies of patients with PD in
Northern Europe, our findings support a strong association
between GBA carrier status and faster progression in motor
symptoms, measured using widely used clinical and patient-
reported measures of motor impairment. These data have
important implications for counseling patients regarding
disease prognosis and for planning and interpreting clinical
trials of disease‐modifying therapies in PD.
GBA-PD has long been associated with a younger onset of
PD and a more malignant disease course, with increased
dementia risk and mortality,3,6–11 but studies evaluating the
progression of motor impairment using the UPDRS, partic-
ularly in early PD, have been surprisingly few and in-
consistent. Only 2 other studies have previously shown an
association ofGBA variants and motor impairment measured
by the UPDRS, and both of these did so only in patients with
more advanced disease. The first followed 13 patients with
PD (average disease duration 7.5 years) and the 2 most
common pathogenic GBAmutations (N370S or L444P) and
26 matched noncarriers, and showed more rapid motor
progression in patients with GBA-PD.8 Subsequently, a large
multicenter study of 733 patients (average disease duration
8.6 years) showed that carriers of aGBA variant experienced a
larger increase in UPDRS motor score compared to non-
carriers.9 Another study looked at the association of 2 in-
dividual GBA variants (N370S or K26R/rs75548401)
selected from the PDgene database and progression of
UPDRS motor score. No significant association was shown
between either variant and the change in UPDRS motor
score measured in participants from the Washington
University cohort and Parkinson’s Progression Markers Ini-
tiative (PPMI) cohorts using UPDRS scores in the “on” or
“off” state.23 Of note, the low observedminor allele frequency
of each variant (N370S 0.007 and K26R 0.012) combined
with moderate sample size and length of follow-up of the
cohorts may account for the lack of significant associations.
The analysis of individual GBA variants may require larger
collaborations; indeed the largest genome-wide association
study of PD clinical phenotypes to date included 12 cohorts
(including PPMI) and whereas no significant associations
were identified with UPDRS motor scores, GBA T369M was
shown to be associated with the faster development of H&Y
stage 3.24 Alternatively, a more comprehensive assessment of
GBA variants using exome sequencing, as done in the present
Table 2 Relationship Between GBA Carrier Status and Change in Unified Parkinson’s Disease Rating Scale (UPDRS) Motor
and Activities of Daily Living (ADL) Scores Using Linear Mixed Effects Models
Subscale
GBA carrier (n = 53)a Mutation carrier (n = 8)a Polymorphism carrier (n = 45)a
β (95% CI) p Value β (95% CI) p Value β (95% CI) p Value
UPDRS motor
Main effectb −0.3 (−3.1 to 2.4) 0.80 1.2 (−5.5 to 7.9) 0.72 −0.6 (−3.5 to 2.3) 0.69
Interaction with timeb 0.9 (0.2 to 1.5) 0.007 1.2 (−0.3 to 2.7) 0.11 0.8 (0.1 to 1.5) 0.022
UPDRS ADL
Main effectb 0.1 (−1.2 to 1.3) 0.92 1.4 (−1.7 to 4.5) 0.37 −0.2 (−1.5 to 1.2) 0.82
Interaction with timeb 0.5 (0.2 to 0.9) 0.003 0.9 (0.1 to 1.7) 0.029 0.4 (0.1 to 0.8) 0.016
Abbreviation: CI = confidence interval.
a GBA carrier status compared to noncarriers: UPDRS motor scores were available for 386 noncarriers and 53 GBA carriers and UPDRS ADL scores were
available for 382 noncarriers and 53 GBA carriers.
b Models adjusted for sex, study cohort, and age and duration of motor symptoms at baseline. The main effect indicates the effect of carrier status on the
intercept and the interaction with time indicates the effect of carrier status on the slope (change in value per year) of the model.
Figure 2 Prediction of Unified Parkinson’s Disease Rating
Scale (UPDRS) Motor Score Over Time
Average predicted UPDRSmotor scores with confidence bands for the first 7
years after diagnosis of PD for carriers of GBA variants (red, diamonds) and
noncarriers (blue, triangles).
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study, could determine whether GBA carrier status affects
motor impairment in these cohorts.
In our population-based study, we followed patients pro-
spectively from the time of PD diagnosis with regular and
structured clinical follow-up for up to 7 years and found
carriers of a GBA variant on average experience a more than
69% greater annual increase in UPDRS motor score com-
pared to noncarriers. Over the course of the study, the model
predicts carriers of a GBA variant will experience on average a
7-point higher increase in UPDRS motor score compared to
the noncarriers. This is considered to represent a moderate to
large clinically important difference in motor function.25 In
support of this, we also show substantial differences in the rate
of functional decline measured by the ADL scores. Our data
add an important missing piece of the puzzle, showing for the
first time that carriers of GBA variants experience a more
aggressive motor disease course from the early phases of PD.
Because GBA variants were associated with more rapid pro-
gression of overall motor symptoms, we further examined
whether and to what extent GBA carrier status was associated
with changes in the severity of specific motor signs. Significant
differences between groups were shown in progression rates
in the subscores related to bradykinesia and rigidity. It is well
known that patients with PD are prone to develop dementia,
with axial impairment being an established clinical risk fac-
tor.26 However, we found no association betweenGBA carrier
status and change in severity of axial symptoms in our study.
In contrast, we observed clear associations with worsening of
bradykinesia and rigidity, which also have been associated
Table 3 Relationship BetweenGBA Carrier Status and Change in Unified Parkinson’s Disease Rating Scale (UPDRS) Motor
Subscores Using Linear Mixed Effects Model
Subscale
GBA carrier (n = 53)a Mutation carrier (n = 8)a Polymorphism carrier (n = 45)a
β (95% CI) p Value β (95% CI) p Value β (95% CI) p Value
Tremorb
Main effectc 0.05 (−0.2 to 0.2) 0.85 0.3 (−0.2 to 0.7) 0.21 −0.0 (−0.2 to 0.2) 0.76
Interaction with timec 0.02 (−0.01 to 0.05) 0.21 −0.04 (−0.12 to 0.04) 0.31 0.03 (−0.00 to 0.07) 0.074
Bradykinesia
Main effectc −0.6 (−2.0 to 0.8) 0.39 −0.3 (−3.7 to 3.2) 0.88 −0.7 (−2.2 to 0.8) 0.38
Interaction with timec 0.49 (0.18 to 0.79) 0.002 0.85 (0.13 to 1.58) 0.021 0.41 (0.08 to 0.75) 0.014
Rigidity
Main effectc 0.4 (−0.4 to 1.2) 0.32 −0.1 (−2.1 to 1.9) 0.92 0.5 (−0.4 to 1.4) 0.25
Interaction with timec 0.17 (0.01 to 0.32) 0.038 0.32 (−0.05 to 0.69) 0.089 0.14 (−0.03 to 0.31) 0.12
Axial impairment
Main effectc −0.1 (−0.7 to 0.6) 0.87 0.0 (−1.6 to 1.6) 1.00 −0.1 (−0.8 to 0.6) 0.86
Interaction with timec 0.10 (−0.07 to 0.27) 0.27 0.09 (−0.32 to 0.50) 0.66 0.10 (−0.09 to 0.29) 0.30
Abbreviation: CI = confidence interval.
a GBA carrier status compared to noncarriers: subscores were available for 386 noncarriers and 53 GBA carriers.
b The tremor and axial impairment scores were log-transformed before analysis.
c Models adjusted for sex, study cohort, and age and duration of motor symptoms at baseline. The main effect indicates the effect of carrier status on the
intercept and the interaction with time indicates the effect of carrier status on the slope (change in value per year) of the model.
Figure 3 Reduced Trial Size in GBA-Targeted Clinical Trials
Compared to the Traditional “All-Comer” Design
Required sample size for clinical trials enrolling only carriers of GBA variants
(red diamonds) or an “all-comer” design with nonselected patients with
Parkinson disease (PD) (black squares) across varying levels of power to
detect a between–within subjects interaction effect. A trial recruiting only PD
carriers of a GBA variant could reduce the size required by threefold for an
intervention indicated to halve the rate of motor decline, measured by the
Unified Parkinson’s Disease Rating Scale (UPDRS) motor score.
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with an increased dementia risk. Interestingly, while advanced
age is considered a major risk factor for PD dementia,27,28 we
and others have previously shown that GBA carriers develop
PD at younger age than noncarriers. Overall, our data suggest
thatGBA is associated with a specific subtype of PDwithmore
rapid motor progression and higher dementia risk despite
lower age at onset and only milder axial symptoms.
We observed that the effect on changes in both the ADL and
motor examination scores was faster in carriers of a GBA mu-
tation compared to carriers of a GBA polymorphism. Similar
results were observed by Davis et al.,9 who reported that the
effect on UPDRSmotor score was slightly more pronounced in
carriers of pathogenic GBA mutations compared to carriers of
the common E326K polymorphism. This observation is also in
line with previous work showing that the effect size associated
with GBA carrier status on cognitive impairment is also on a
continuum.3,9–11 Our findings reaffirm the importance of the
severity of theGBA variant on the progression of disease in PD.
It is established that GBA carriers have an earlier age at PD
onset but there are conflicting reports of the presenting
symptoms in GBA-PD compared to idiopathic forms of the
disease.29–32 In our study, patients with PD-associated GBA
mutations appeared clinically indistinguishable from newly
diagnosed patients with idiopathic PD. This is in agreement
with the only other population-based study to assess GBA
carriers at the time of PD diagnosis, which found that patients
with GBA-PD had a similar motor profile compared to non-
carriers.3 Although we would not yet advocate for routine
genetic testing, these data suggest that screening for GBA
variants might be helpful as part of a model to identify those at
risk of a more malignant disease course at diagnosis.
TheUPDRSmotor score is one of themost common outcomes
in observational studies and clinical trials, used to measure the
severity of PD impairment. The advantages as a primary out-
come include good intrarater and inter-rater reliability but, as
has been shown in this study, genetic heterogeneity in pop-
ulations can substantially influence the change inUPDRSmotor
scores over time. We show that the GBA-PD subgroup, which
constitutes about 12% of the PD population, are predicted to
show on average 69% more rapid motor progression than the
noncarriers. If not accounted for, differences in GBA carrier
distribution by treatment arm (which can arise by chance even
during randomization) could thus influence trial outcome and
lead to invalid conclusions. Balancing treatment arms with
stratification of randomization according to GBA status would
avoid this potential problem in future trials.
A major challenge for drug development in neurodegenera-
tive diseases is that adequately powered trials typically require
several hundred participants and long durations. The expec-
ted progression of the trial’s primary outcome in genetic
subgroups can be used to improve the efficiency and effec-
tiveness of clinical trials. The utility of this model in GBA-PD
was assessed by comparing simulated randomized placebo-
controlled trial designs to recruit all newly diagnosed patients
with PD (all-comers) or only those predicted to be at risk of a
faster motor decline, by limiting trial selection to carriers of a
GBA variant. We show that a trial limited to GBA carriers
could recruit up to 65% fewer participants than a traditional
all-comer design, which could feasibly translate into consid-
erable savings in costs. Our data are in line with and extend on
previous estimations targeting only patients with a GBA
mutation (such as L444P) for a hypothetical trial with MMSE
as the primary outcome.11 Notably, this hypothetical trial was
found to reduce trial size by as much as 25-fold compared to a
trial of patients with PD without aGBAmutation.11 However,
neuropathic GBA mutations are rare in the general PD pop-
ulation (1.4% in our study), whereas we considered all types
ofGBA variant and thus substantially increased the number of
eligible trial participants. In light of this, the threefold re-
duction in trial size shown here is more realistic in a
population-based setting. The first example of a trial studying
ambroxol in genetically defined patients with PD was recently
published,33 and although this trial was not powered to assess
the clinical efficacy of the drug, it demonstrates the potential
of using genetic information to balance or build a trial.
Our study is not without limitations. The modest sample size
of each genotype group prevented the assessment of in-
dividualGBAmutations and larger longitudinal studies will be
needed to determine whether the risk for motor progression
varies across individual GBA variants. The use of a linear
model provides an approximation of overall disease pro-
gression, as patients tend to improve during the first year after
initiating medication before worsening again, and future
studies should also examine possible differences in the re-
sponse to medication in GBA-associated PD. Strengths of our
study include the large number of participants with newly
diagnosed PD with longitudinal data available for inclusion,
the uniform study designs of the 3 cohorts, length of follow-up
(median 7 years), the number of visits analyzed per partici-
pant (median 8 visits), and the exceptionally low attrition rate.
Furthermore, each of the cohorts are population-based
studies, which avoids some of the pitfalls when cases are
recruited from neurology and memory clinics. This means
that our findings that GBA variants are linked to more rapid
motor progression in PD are likely to be applicable to the
general PD population. Motor decline has a major bearing on
independence, nursing home admission, caregiver burden,
and mortality in PD,34 and better understanding and pre-
diction of PD progression could improve disease manage-
ment for a meaningful proportion of patients and has direct
implications for improving the design of clinical trials.
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